AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$QNRX

Culverwell Anthony James purchased $30K of QNRX

Culverwell Anthony James purchased 6,146 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.

Original reporting
SEC EDGAR · Culverwell Anthony James
Published Sep 2, 2026, 1:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 1:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$QNRX
Neutral
medium confidence
Mentioned
$QNRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QNRXNeutralLow
01

Why it matters

The director's purchase modestly raises his stake, offering a slight positive signal but unlikely to affect market pricing.

02

Market read

Primary insider purchase provides new, low‑impact information for traders monitoring QNRX.

03

What to watch

Potential upcoming clinical trial milestones could make the insider buy more meaningful if disclosed later.

Relevance 4/10Novelty 5/10Timing: filing today

Background

Form 4 filing discloses insider transactions; provides transparency on director holdings.

Company-level read

Ticker impact

$QNRXNeutralMedium confidence
Context

Director Culverwell Anthony James bought 6,146 shares for $29,992, raising his holding to 40,364 shares.

Expected impact

minimal impact on QNRX price in the short term

Evidence & confidence

Purchase size ($30K) is small relative to market cap and float; director role adds some weight but not enough for a significant market reaction.

Market effects

Sector

Limited effect on biotech sector; typical insider buys are common and do not shift sector sentiment.

Regional

No notable regional impact; company is US‑listed.

Global

Low global relevance; isolated insider transaction.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong confidence signal.

Key entities

  • Individual
    Culverwell Anthony James

    Director of Quoin Pharmaceuticals, Ltd.

  • Company
    Quoin Pharmaceuticals, Ltd.

    Biotech firm listed on Nasdaq under ticker QNRX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

QNRX insider trading history →

Related articles

SEP 8
$QNRXMedAI 8/10

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals (QNRX) announced FDA granted Rare Pediatric Disease Designation for QRX003, its treatment for Peeling Skin Syndrome. This is the second such designation for QRX003, following one for Netherton Syndrome. If approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 study in 2H 2026, enrolling up to 12 patients. There are currently no approved treatments for Peeling Skin Syndrome.

globenewswire.com2 min
AUG 28
$AEMDHighAI 8/10

Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.

rttnews.com3 min
AUG 28
$QNRXHighAI 9/10

Quoin Pharma Reports Positive Interim Data From Ongoing Phase 2/3 Study Of QRX003

Quoin Pharmaceuticals (QNRX) reported positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome. Four of six patients showed significant improvement. The company expects to complete recruitment by the end of 2026 and report topline data in Q2 2027. If approved, QRX003 could be the first FDA-approved treatment for the condition. QNRX shares rose 55% to $7.99 in pre-market trading.

rttnews.com2 min
AUG 14
$QNRXMed

Quoin Pharmaceuticals, Ltd. (QNRX): Results of Operations and Financial Condition

Quoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Com

SEC EDGAR 8-K6 min